Single Cell Sequencing Company Singleron Biotechnologies Received Around $14 Million In Series Pre-A Financing

According to PE Daily, Singleron Biotechnologies, a company specializing in clinical applications for single-cell sequencing just received around $14 million in Series Pre-A financing. This round of financing was led by Sherpa Capital and followed by China Growth Capital and Frees Fund.

This round of funds will be used to accelerate the clinical application of Singleron Biotechnologies' massive single-cell sequencing technology, new product development, laboratory building, single-cell database building and marketing team expansion.

Founded in January 2019, Singleron Biotechnologies is committed to developing a simple and reliable mass single-cellomics technology, making it a new generation of molecular diagnostic tools for health management. Currently, the company has laboratories and office buildings in Nanjing and Suzhou.

At present, the market size of single-cell analysis has exceeded 10 billion RMB. In January 2019, Singleron Biotechnologies launched the first massive single-cell sequencing product in China, GEXSCOPE massive single-cell RNA sequencing device. In addition, the company is now working with dozens of hospitals at home and abroad to advance the development of single-cellomics.

Sherpa Capital is a venture capital investment company in Beijing.

China Growth Capital is a VC firm that invests in early-stage consumer and technology companies in China and the United States.

Frees Fund is a venture capital firm that provides both early and growth stage investment to technology startups in both China and the United States.